On 14 August 2026, ジーエヌアイグループ raised its revenue forecast by 74.3%, from ¥27.158 billion to ¥47.327 billion. The earnings forecast remains undisclosed, and F351 revenue has not been included in the latest forecast.
Following the acquisition of あゆみ製薬ホールディングス as a wholly owned subsidiary, ジーエヌアイグループ significantly raised its full-year revenue forecast. The new forecast was increased substantially from ¥27.158 billion before the upward revision to ¥47.327 billion.
The upward revision reflects the impact of the acquisition of あゆみ製薬, whose contribution for the second half was included in consolidated results. The acquisition consideration comprised ¥18.004 billion in cash and ¥26.770 billion in GNI shares, for a total of ¥44.775 billion, and the company borrowed ¥20 billion to fund the transaction.
The earnings forecast remains undisclosed because of uncertainties including preparations for the launch of F351, research and development expenses, and acquisition-related costs. F351 revenue has not been included in the latest forecast.
The items currently confirmed are completion of the acquisition, the consideration, borrowings, the revision to the revenue forecast, and the decision not to disclose the earnings forecast. Other orders, acquisitions, business performance and effects on the share price remain unconfirmed.